Targeting growth hormone in cancer: future perspectives

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Decades of research indicate a significant role for growth hormone (GH) in cancer development and progression.
• The GH signaling pathway is increasingly recognized as a potential therapeutic target in oncology.

Purpose of the Study:

• To review the current understanding of GH's role in cancer.
• To discuss the challenges and considerations for translating GH antagonists into clinical practice.
• To highlight the need for predictive biomarkers in GH-targeted cancer therapy.

Main Methods:

• Review of published preclinical and clinical research on GH and cancer.
• Analysis of xenograft studies evaluating GH antagonists.
• Discussion of translational challenges and biomarker strategies.

Main Results:

• GH antagonists have shown efficacy in preclinical xenograft models, both as single agents and in combination therapies.
• Identification of predictive biomarkers is crucial for patient selection and monitoring treatment efficacy.
• Pharmacological suppression of GH signaling may offer a novel approach to cancer risk reduction.

Conclusions:

• Targeting the GH signaling pathway holds promise for novel cancer therapies.
• Overcoming translational challenges, including biomarker development, is essential for clinical success.
• Further research is needed to determine the full potential of GH-targeted drugs in cancer treatment and prevention.